Tag - ATAI

Developments

IntelGenx updates atai collaboration as first-in-human study launched of an oral film psychedelic drug candidate

IntelGenx (TSX:IGX; OTCQB:IGXT) updated its collaboration with strategic partner, atai Life Sciences (NASDAQ:ATAI), which has begun a first-in-human Phase 1 study for the development of novel formulations of...

October 13, 2022

Developments

atai unit initiates Phase 1 trial for MDMA derivative EMP-01

EmpathBio, a unit of atai Life Sciences (NASDAQ:ATAI), received regulatory and ethics approval to begin enrollment of its Phase 1 study of EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for the treatment...

September 28, 2022

Developments

atai Life Sciences amends loan agreement to support IntelGenx upgrade to TSX

atai Life Sciences (NASDAQ;ATAI) amended a loan agreement with IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) to support IntelGenx’s conditionally approved graduation from the TSX Venture Exchange to the Toronto Stock...

September 15, 2021

Developments

atai Life Sciences prices $225-million IPO

atai Life Sciences (NASDAQ:ATAI) priced an initial public offering of 15 million common shares at $15 each for gross proceeds of $225-million. In its first day of trading on June 18, the stock jumped $4.45, or 29%, to...

June 18, 2021

Tag - ATAI

IntelGenx updates atai collaboration as first-in-human study launched of an oral film psychedelic drug candidate

atai unit initiates Phase 1 trial for MDMA derivative EMP-01

atai Life Sciences amends loan agreement to support IntelGenx upgrade to TSX

atai Life Sciences prices $225-million IPO

General

More